Taikang
Taikang Life Building, 156 Fuxingmennei Street, Beijing, 100031, China
Overview
Taikang Insurance Group was established in 1996 and is headquartered in Beijing. It has developed into a large insurance financial service group covering insurance, asset management, and medical care. Taikang Insurance Group owns Taikang Life Insurance, Taikang Assets, Taikang Pension, Taikang Jiantou, Taikang Health, Taikang Online, and other subsidiaries. The business scope covers a wide range of areas including life insurance, Internet property insurance, enterprise annuity, asset management, medical pension, health management, and commercial real estate. As of the end of 2017, the assets under management exceeded RMB 1.2 trillion. Since its establishment 22 years ago, the Group has provided a total of 225 million customer service customers and over 340,000 service enterprise customers. The accumulated payment of claims amounted to 35.1 billion yuan and accumulated tax payment of 37.5 billion yuan. It has been ranked among the “Top 500 Chinese Enterprises” for 14 consecutive years. In 2018, Taikang Insurance Group ranked No. 489 in the Fortune Global 500 list with an operating income of US$24.085 billion, marking Taikang's entry into the ranks of the world's largest insurance financial services group. Taikang Insurance Group has always adhered to the concept of “professionalization, marketization, and standardization”, and has deepened the life insurance industry chain. Through 3,900 offline physical networks, online internet platforms and 700,000 employees and salesmen across the country, relying on “vigorous pension, The four-in-one business model of high-end medical care, excellent financial management, and ultimate care builds a healthy ecosystem of the big health industry. Committed to becoming the world's leading insurance financial services group, making insurance more secure, more convenient and more affordable, making people healthier, longer life and richer, making Taikang a part of people's happy life. Taikang Insurance Group integrates the whole life industry chain through the cross-border integration of virtual insurance products and physical medical services to implement a healthy China strategy. As the first pilot enterprise in China's insurance industry to invest in old-age care communities, the Group has completed the layout of pension communities in key cities such as Beijing, Shanghai, Guangzhou, Sanya, Suzhou, Chengdu, Wuhan, Hangzhou, Nanchang, Xiamen, Shenyang and Changsha, becoming the largest in the country. One of the high quality chain pension groups. Adhering to the concept of medical integration, the rehabilitation community with rehabilitation and geriatrics is built in the old-age community to build a Taikang international standard rehabilitation system. At present, the Group has invested in the operation of Taikang Xianlin Drum Tower Hospital, the construction of Taikang Tongji (Wuhan) Hospital, the launch of Taikang Southwest Medical Center, and efforts to build a number of medical education and research integrated medical centers. Taikang Insurance Group adheres to the concept of “serving the public and giving back to the society” and actively fulfills its corporate social responsibility. Especially in the fields of education and academics, a comprehensive education donation system has been formed from primary schools, middle schools, universities to China's economic theory innovation awards. Through the non-profit art organization “Tai Kang Space”, it sponsored and supported the development and research of Chinese contemporary art, and launched “Yi Cai”. The Public Welfare Program continues to support life and big health charity initiatives, and we donate to the nursing homes throughout the country to let more elderly people enjoy their happy and happy years. At present, the personal donation amount of the group and Chairman Chen Dongsheng has reached 430 million yuan.
- Total investments
- 10
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Asset Management
- Financial Services
- Health Insurance
- InsurTech
Investment portfolio
- XISOFT
Led · Series B · Mar 2022
熙软科技 is a specialized information-technology and big-data service provider focused on hospital economic operation management. It maintains a product portfolio of more than 20 independently owned software products, including “熙软HRP” and “熙云平台,” and has developed a complete product system. The company offers systematic solutions for hospital operations management covering economic and operational needs. Recently, 熙软科技 completed a Series C financing round. Proceeds from the round will be directed primarily toward development of the Hospital Operation Data Center (ODR) product. The company also plans to invest in research, development, and promotion of artificial intelligence products and applications. 熙软科技 is a hospital operations management digital service leader that develops Hospital Resource Planning (HRP) solutions and related platforms. The company offers a product suite including "熙软 HRP" and "熙云平台," with more than 30 independently owned software products covering budget management, department and disease costing, materials and supplier platforms, contract and asset management, reconciliation, reimbursement, HR, party affairs, financial accounting, mobile apps, and operational decision tools. Its founding team has deep domain expertise in hospital operations and digitalization and emphasizes digitizing business modules to build a hospital "smart management brain." The company is headquartered in Shanghai and maintains branches in Beijing, Xi'an, Harbin, Chongqing, Hohhot, and Jinan, with nationwide sales and service coverage through local partners. 熙软 reports validated product maturity and industry recognition, including positive assessment from the China Software Testing Center, and has implemented its restructured products in over a hundred medical institutions. Management says it began full market rollout this year and expects significant growth as hospitals accelerate digital and intelligent operations.
- Hong Kong Asia Heart Centre
Participated · Series D · Feb 2022
Hong Kong Asia Medical Group is a cardiovascular specialty medical group founded in 1999 that operates hospitals and services across mainland China, Hong Kong and Japan. The group traces its origins to Wuhan Asia Heart Hospital and has treated about 5 million patients over 22 years. It emphasizes clinical care alongside research and education and has built an internationalized management and talent-development system. The group cites strengths in clinical service capabilities, hospital management replication, clinical innovation translation, and joint talent training. Financially, the company recently completed a $400 million Series D financing. Management says proceeds will support service innovation, continued expansion, and the goal of becoming an international first-class integrated cardiac medicine group combining treatment, patient care, research and education.
- Sanbo Brain Hospital
Led · Series B · May 2020
Sanbo Brain is a specialty medical group focused on neurological care, integrating clinical services, teaching and research across its hospitals. Founded in 2004, the group operates seven large hospitals (one under construction) covering Beijing, Chongqing, Hunan, Fujian, Henan and Yunnan. Its flagship, Capital Medical University Sanbo Brain Hospital, is repeatedly ranked among the top neurosurgery centers in Beijing. The group centers its clinical strength on a roster of senior neurology and neurosurgery experts and has built systematic talent training and research capabilities. Sanbo says it will increase investment in research translation, talent reserves and medical hardware while rolling out a regional network to achieve scaled growth. Financially, Sanbo Brain recently completed a B‑round equity financing of over RMB 800 million, which the company says will support nationwide expansion and consolidation of its brand and services.
- Antengene Corporation
Participated · Series B · Jan 2019
Antengene Corporation is a Shanghai, China-based hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies. Led by Dr. Jay Mei, Founder, Chairman and CEO, the company operates integrated drug discovery, clinical development, manufacturing and commercialization anchored in the Asia Pacific region with a global layout. Antengene has a broad pipeline including six clinical-stage programs and six pre-clinical oncology assets. Notable programs include ATG-010 (selinexor), ATG-008 (onatasertib), ATG-016 (eltanexor), ATG-019 (PAK4/NAMPT dual-target inhibitor) and ATG-017 (ERK1/2 inhibitor). The company intends to use the proceeds from its recent financing to continue clinical development, expand in-house R&D capabilities and strengthen commercial infrastructure in APAC markets. In April 2017 Celgene became a founding partner and obtained an equity position in Antengene. Antengene is a Chinese clinical-stage biopharmaceutical company focused on developing and commercializing novel oncology therapeutics. Its pipeline includes five clinical-stage products ranging from Phase 2/3 to NDA stage, led by ATG-008 and ATG-010 (selinexor). ATG-010 is being developed for relapsed/refractory multiple myeloma, lymphomas and solid tumors, while ATG-008 is in a multi-regional trial enrolling late-stage HCC patients in Taiwan, South Korea and mainland China. Two other candidates, ATG-016 and ATG-019, are in Phase 1/2 studies across multiple cancer types including MDS, colorectal and prostate cancers. ATG-527 completed a Phase 1 trial and is being explored for multiple antiviral indications including influenza, RSV and EBV-related diseases. The company intends to use recent proceeds to advance lead programs and other clinical-stage assets, expand its pipeline via internal R&D and external partnerships, and prepare commercial launch of late-stage candidates.
- Hangzhou Just Biotherapeutics (Just China)
Participated · Series B · Jun 2018
Hangzhou Just Biotherapeutics develops antibody and recombinant protein therapeutics and a biomanufacturing/process development platform in partnership with Seattle-based Just Biotherapeutics Inc. The company focuses on therapies for oncology, genetic rare diseases and metabolic diseases. It employs nearly one hundred scientists and engineers across sites in Hangzhou and Boston and is led by founder and CEO Yining Zhao. HJB was founded in 2016 by former Amgen and Genentech executives in Hangzhou, China. The company intends to use the new funds to enhance R&D capabilities and accelerate clinical trials globally. Its platform aims to reduce cost and speed development while maintaining global quality standards.
Team
Chen Dongsheng
Founder , Chairman & CEO